LYON, France et CAMBRIDGE, Mass., 07 juin 2023 (GLOBE NEWSWIRE) – Amolyt Pharma, a company specializing in the development of therapeutic peptides targeting rare endocrine and metabolic diseases, announced today that it was organizing an event with opinion leaders on eneboparatide, its lead experimental drug candidate for the treatment of hypoparathyroidism. It will be held on Friday, June 16, 2023 at 8:30 AM CT (9:30 AM ET) at the Sheraton Grand Chicago Riverwalk in Chicago, Illinois, USA. The event will also be broadcasted online for those unable to attend in person.
Aliya Khan, MD, FRCPC, FACP, FACE, FASBMR (McMaster University Medical Centre) will address the unmet medical needs of patients with hypoparathyroidism and present the full results of the phase 2a trial of eneboparatide, a parathyroid hormone receptor 1 (PTHR1) agonist with an innovative mechanism of action.
Patty Keating, a patient and president of the HypoPARAthyroidism association, will share her personal experience of the disease and the challenges posed by the current standard of care.
Mark Sumeray, MD, medical director of Amolyt Pharma, will provide an update on the Calypso study, the phase 3 clinical trial of eneboparatide for the treatment of patients with hypoparathyroidism.
The presentations will be followed by a live Q&A session. To register for the event, click here.
About Hypoparathyroidism:
Hypoparathyroidism is characterized by a deficiency of parathyroid hormone (PTH) that leads to hypocalcemia and high levels of phosphorus in the blood. Approximately 80,000 people in the US and 110,000 in Europe suffer from hypoparathyroidism, of which 80% are women. Despite available treatments, patients suffer from persistent and severe symptoms. They often develop complications and comorbidities that affect their quality of life, representing populations with specific clinical needs. Clinical manifestations vary and can affect many tissues and organs, particularly the kidneys and bones.
17% of hypoparathyroidism patients suffer from osteopenia or osteoporosis, and 53% are peri- or postmenopausal women who are likely to develop osteoporosis. It is also estimated that 26% of hypoparathyroidism patients suffer from chronic kidney disease or renal failure, which justifies the therapeutic need to reduce urinary calcium excretion.
About Eneboparatide:
Eneboparatide is an experimental therapeutic peptide that selectively acts on a specific conformation of the parathyroid hormone receptor (PTH) to induce a prolonged effect on calcium metabolism and thus control the symptoms of hypoparathyroidism. Its action could also limit urinary calcium excretion by restoring calcium reabsorption by the kidney, with the aim of preventing chronic kidney diseases. In addition, eneboparatide’s unique mode of action and short half-life should preserve bone integrity, a major potential benefit given that the majority of hypoparathyroidism patients are peri- or postmenopausal women, often at risk of osteoporosis.
About Amolyt Pharma:
Amolyt Pharma, a clinical-stage biotechnology company, relies on the expertise and experience of its team to develop treatments aimed at improving the lives of patients with rare endocrine diseases. Its development portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma intends to continue building its product portfolio based on its global network in the field of endocrinology and with the support of its syndicate of international investors. For more information, visit https://amolytpharma.com/ or follow us on Twitter @AmolytPharma and LinkedIn.
Media Relations:
Jordyn Temperato
Communications LifeSci
[email protected]
Investor Relations:
Ashley Robinson
LifeSci Advisors, LLC
[email protected]
+1.617.430.7577
#Amolyt #Pharma #organise #juin #Chicago #événement #hybride #avec #des #leaders #dopinion #sur #lénéboparatide #agoniste #PTHR1 #entrant #phase #pour #traitement #lhypoparathyroïdie
publish_date]
